Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 9;8(4):746.
doi: 10.3390/vaccines8040746.

Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials

Luca Tudor Giurgea  1 , Matthew James Memoli  1
Affiliations
Review

Navigating the Quagmire: Comparison and Interpretation of COVID-19 Vaccine Phase 1/2 Clinical Trials

Luca Tudor Giurgea et al. Vaccines (Basel). .

Abstract

Vaccines against Coronavirus Disease 2019 Originated-19) have been developed with unprecedented rapidity, many utilizing novel strategies. As of November 2020, a series of publications have outlined the results of phase 1/2 studies of nine different vaccines planned to move forward to phase 3 trials. The results are encouraging, demonstrating a paucity of severe or serious adverse events and robust induction of antibody titers. Determination of the vaccine candidates with the highest protective efficacy and best adverse event profiles will be essential in refining public health strategies. However, differences in study design and reporting of data make comparisons of existing phase 1/2 studies difficult. With respect to safety, studies have variable follow-up times and may use different definitions for adverse events. Immunogenicity outcomes are even more inconsistent, with variations in timepoints and critical differences in the types of antibodies studied as well as methodological differences in assays. Furthermore, the correlates of protection in COVID-19 are not known. Harmonization of phase 3 trial designs and use of objective and meaningful clinical outcomes will be crucial in streamlining future global responses to the pandemic.

Keywords: COVID-19; SARS-COV-2; clinical trials; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. World Health Organization COVID-19 Weekly Epidemiological Update. [(accessed on 28 November 2020)]; Available online: https://www.who.int/publications/m/item/weekly-epidemiological-update---....
    1. Armocida B., Formenti B., Ussai S., Palestra F., Missoni E. The Italian health system and the COVID-19 challenge. Lancet Public Health. 2020;5:e253. doi: 10.1016/S2468-2667(20)30074-8. - DOI - PMC - PubMed
    1. Emanuel E.J., Persad G., Upshur R., Thome B., Parker M., Glickman A., Zhang C., Boyle C., Smith M., Phillips J.P. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N. Engl. J. Med. 2020;382:2049–2055. doi: 10.1056/NEJMsb2005114. - DOI - PubMed
    1. Slaoui M., Hepburn M. Developing Safe and Effective Covid Vaccines-Operation Warp Speed’s Strategy and Approach. N. Engl. J. Med. 2020;383:1701–1703. doi: 10.1056/NEJMp2027405. - DOI - PubMed
    1. Zhu F.C., Li Y.H., Guan X.H., Hou L.H., Wang W.J., Li J.X., Wu S.P., Wang B.S., Wang Z., Wang L., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/S0140-6736(20)31208-3. - DOI - PMC - PubMed

LinkOut - more resources